| Full text | |
| Author(s): |
Santos, Nilton Jose
[1, 2]
;
Barquilha, Caroline Nascimento
[1, 2]
;
Barbosa, Isabela Correa
[1, 2]
;
Macedo, Rodrigo Tavares
[3]
;
Lima, Flavio Oliveira
[3]
;
Justulin, Luis Antonio
[1]
;
Barbosa, Guilherme Oliveira
[2]
;
Carvalho, Hernandes F.
[2]
;
Felisbino, Sergio Luis
[1]
Total Authors: 9
|
| Affiliation: | [1] Sao Paulo State Univ, Inst Biosci Botucatu IBB, Dept Struct & Funct Biol, BR-18618689 Botucatu, SP - Brazil
[2] UNICAMP State Univ Campinas, Inst Biol IB, Dept Struct & Funct Biol, BR-13083970 Campinas, SP - Brazil
[3] Sao Paulo State Univ, Botucatu Sch Med FMB, BR-01049010 Botucatu, SP - Brazil
Total Affiliations: 3
|
| Document type: | Journal article |
| Source: | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES; v. 22, n. 16 AUG 2021. |
| Web of Science Citations: | 0 |
| Abstract | |
Prostate cancer (PCa) is the leading cause of cancer-associated mortality in men, and new biomarkers are still needed. The expression pattern and protein tissue localization of proteoglycans of the syndecan family (SDC 1-4) and syntenin-1 (SDCBP) were determined in normal and prostatic tumor tissue from two genetically engineered mouse models and human prostate tumors. Studies were validated using SDC 1-4 and SDCBP mRNA levels and patient survival data from The Cancer Genome Atlas and CamCAP databases. RNAseq showed increased expression of Sdc1 in Pb-Cre4/Pten(f/f) mouse Pca and upregulation of Sdc3 expression and downregulation of Sdc2 and Sdc4 when compared to the normal prostatic tissue in Pb-Cre4/Trp53(f/f)-;Rb1(f/f) mouse tumors. These changes were confirmed by immunohistochemistry. In human PCa, SDC 1-4 and SDCBP immunostaining showed variable localization. Furthermore, Kaplan-Meier analysis showed that patients expressing SDC3 had shorter prostate-specific survival than those without SDC3 expression (log-rank test, p = 0.0047). Analysis of the MSKCC-derived expression showed that SDC1 and SDC3 overexpression is predictive of decreased biochemical recurrence-free survival (p = 0.0099 and p = 0.045, respectively), and SDC4 overexpression is predictive of increased biochemical recurrence-free survival (p = 0.035). SDC4 overexpression was associated with a better prognosis, while SDC1 and SDC3 were associated with more aggressive tumors and a worse prognosis. (AU) | |
| FAPESP's process: | 16/09532-3 - Prostate cancer: changes in the Syndecan proteoglycans, oxidative stress enzyme sulfiredoxin and cell cycle kinase MELK |
| Grantee: | Sérgio Luis Felisbino |
| Support Opportunities: | Regular Research Grants |
| FAPESP's process: | 19/19644-1 - Prostate cancer: involvement of adiponectin and type X collagen pathways |
| Grantee: | Sérgio Luis Felisbino |
| Support Opportunities: | Regular Research Grants |
| FAPESP's process: | 15/26175-7 - Stromal alterations in prostate cancer: a study on Syndecan proteoglycans family in two knockout mouse model - PTEN-/- e Rb1-/- Trp53-/- |
| Grantee: | Nilton José dos Santos |
| Support Opportunities: | Scholarships in Brazil - Master |